Head-to-head · WeighScore
Next Vial vs PrescribedRX
The verdict
Next Vial takes it — 59.3/100 to 59/100, but only just.
Next Vial grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options. PrescribedRX is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Next Vial | PrescribedRX |
|---|---|---|
| WeighScore | 59.3/100 | 59/100 |
| Grade | C | C |
| Scorecard rank | #345 | #351 |
| Semaglutide | $250/mo (compounded) | $189/mo (compounded) |
| Tirzepatide | Not disclosed | $276/mo (compounded) |
| Coverage | 49 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #345 · C
Strengths
- LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
- No membership fees — one all-in price covering consultation, medication, and shipping
- Compounded semaglutide, tirzepatide, and microdose options available
- Free rushed shipping; serves 49 states nationwide
- Board-certified physician oversight with ongoing provider support
Where it loses points
- Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
- Compounded medications are not FDA-approved
- Labs and nutritional coaching not disclosed
- Microdose pricing not published on product page
- Alaska not listed among served states
Graded #351 · C
Strengths
- Compounded semaglutide ($189/mo) and tirzepatide ($276/mo) injectables, with lower per-month pricing on the 3-month plans ($176 and $233/mo)
- Clear, upfront plan pages showing monthly and multi-month pricing with no surprise fees
- Care from licensed US providers with monthly home delivery and ongoing dose support
- Bilingual English/Spanish site and a broader telehealth menu (TRT, longevity, hair, sexual health) for people who want more than weight loss
Where it loses points
- Doesn't publish the states it serves — you only learn eligibility after starting the intake
- Compounding pharmacies aren't named on the site
- Mid-range pricing — cheaper compounded GLP-1 options exist and the 3-month discount is modest
- Compounded semaglutide and tirzepatide injectables only — no brand-name or oral options
- Self-hosted affiliate program (not a vetted network); Florida/Palm Beach framing suggests a regional lean
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.